News | August 10, 2023
SMS Lifesciences India posts Q1 FY24 consolidated loss at Rs. 1.79 Cr
The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023
The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
To enable company to be future-ready by tapping potential in CDMO space
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
The company is addressing these observations
ELL will be the preferred source of supply for some the key Raw Materials to VPPL at "Arm's Length" transaction.
Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore
Subscribe To Our Newsletter & Stay Updated
